Video

Dr. Yardley Shares Insight on the Impact of Biosimilars

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

The role of biosimilars is a moving target right now, and community oncologists are waiting to see how the implementation of biosimilars would fit into practice, Yardley says. Sarah Cannon Research Institute has had a number of biosimilar clinical trials come its way, but they have yet to participate in them. Yardley says that she understands the need for biosimilars and the potential benefit to patients, but right now her practice is a proponent of standard drugs.

Several biosimilars have been approved by the FDA, including the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst) for use in patients with HER2-positive breast cancer. Phase III data from the HERITAGE trial presented at the 2018 ASCO Annual Meeting indicated clear equivalence for MYL-1401O compared with standard trastuzumab. MYL-1401O combined with taxane-based chemotherapy for frontline treatment of patients with HER2-positive disease mirrored the progression-free survival of patients treated in the same setting with trastuzumab.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD